the presumptive leader is not defined, which leads to uncertainty and delays when leadership and action is needed,'' the report says.
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.
lea ament, left, and tamara nunley talk about the care their team provided for helen and robert valenzuela at st. jude medical center in fullerton. (scott smeltzer / staff photographer)
.
.